Recommended Readings: James P. Allison, Ph.D., Friday May 12th, 2017

Friday Lectures

Friday, May 2, 2017  3:45 p.m.

Caspary Auditorium

James P. Allison, Ph.D.

Professor and Vivian L. Smith Distinguished Chair of Immunology,

Executive Director of the Immunotherapy Platform

The University of Texas MD Anderson Cancer Center

Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities, and Prospects for a Cure

Recommended Readings:

http://thetartan.org/2017/5/1/scitech/immunotherapy

Hazarika M; Chuk MK; Theoret MR; et al. (2017). U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.CLINICAL CANCER RESEARCH. doi: 10.1158/1078-0432

Medina, Patrick J.; Adams, Val R. (2016). PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. PHARMACOTHERAPY. 36(3): 317-334

Sharma, Padmanee; Allison, James P. (2015). Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. CELL. 161(2): 205-214

Robert, Caroline; Schachter, Jacob; Long, Georgina V.; et al. (2015). Pembrolizumab versus Ipilimumab in Advanced Melanoma. NEW ENGLAND JOURNAL OF MEDICINE    372(26): 2521-2532

Sharma, Padmanee; Allison, James P. (2015). The future of immune checkpoint therapy. SCIENCE. 348(6230): 56-61

Gubin, Matthew M.; Zhang, Xiuli; Schuster, Heiko; et al. (2014). Checkpoint blockage cancer immunotherapy targets tumour-specific mutant antigens. NATURE. 515(7528): 577-+

Lipson, Evan J.; Drake, Charles G. (2011). Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. CLINICAL CANCER RESEARCH. 17(22): 6958-6962

 

Recommended Readings: Sohail Tavazoie, Ph.D. October 6

Monday Lecture Series
Monday, October 6, 2014
3:45 p.m., Caspary Auditorium

Sohail Tavazoie, Ph.D.
Leon Hess Assistant Professor and Head,
Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology,
The Rockefeller University
Senior Attending Physician,
The Rockefeller University Hospital

Molecular Control of Cancer Metastasis

Recommended Readings

Empirical Articles

Pencheva, N., Tran, H., Buss, C., Huh, D., Drobnjak, M., Busam, K., & Tavazoie, S. F. (2012). Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell, 151(5), 1068–1082. doi:10.1016/j.cell.2012.10.028

Png, K. J., Halberg, N., Yoshida, M., & Tavazoie, S. F. (2012). A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature, 481(7380), 190–194. doi:10.1038/nature10661

Png, K. J., Yoshida, M., Zhang, X. H.-F., Shu, W., Lee, H., Rimner, A., … Tavazoie, S. F. (2011). MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes & Development, 25(3), 226–231. doi:10.1101/gad.1974211

Tavazoie, S. F., Alarcón, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P. D., … Massagué, J. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451(7175), 147–52. doi:10.1038/nature06487

Review Papers

Pencheva, N., & Tavazoie, S. F. (2013). Control of metastatic progression by microRNA regulatory networks. Nature Cell Biology, 15(6), 546–54. doi:10.1038/ncb2769